Prof. Hubert Hondermarck

Biography

Hubert Hondermarck is Professor of Medical Biochemistry. He obtained a PhD in neurobiochemistry and was a post-doctoral fellow at the University of California Irvine where he investigated growth factor signalling in neuronal cells using proteomics. He took an academic position at the University of Lille (France) in 1993 and started working on breast cancer cell growth and metastasis. He became full Professor in 1998 and a member of the "Institut Universitaire de France" in 2002. He created and directed for 10 years a research unit of the French Institute of Health and Medical Research (INSERM) studying breast cancer cell signalling. In 2011, he moved to the University of Newcastle Australia, to start a new group investigating the role of neurotrophins and their receptors in various tumours, with a particular interest for their clinical utility as biomarkers and therapeutic targets. His long-term interest is in the relationship between the nervous system and cancer.

He has published 76 PubMed referenced articles on cancer cell biology and cancer proteomics http://www.ncbi.nlm.nih.gov/pubmed?term=hondermarck. He has edited a book on biomedical and pharmaceutical applications of proteomics http://www.springerlink.com/content/978-1-4020-2322-4/. He has two internationally issued patents and several collaborations and research contracts with biopharmaceutical companies.

He is on the Editorial Board of: Molecular and Cellular Proteomics (ASBMB), Proteomics Clinical Applications (Wiley), Recent Patent on Anti-Cancer Drug Discovery (Bentham), Open Cancer Journal (Bentham) and Frontiers in Molecular and Cellular Endocrinology (Frontiers Media).

He is a member of the Board of Directors of the Human proteome Organization (HUPO) since 2006.

Qualifications

• PhD (Life Sciences & Health), University of Lille - France, 1990

Research

Research keywords

• Cancer Biology and Translational Cancer Research
• Proteomics

Research expertise

Tumor cell growth and metastasis / Growth Factor Signalling / Cancer proteomics / Neurotrophins and their receptors / Breast cancer.

Recent selected publications by Hubert Hondermarck:

Demont Y, Corbet C, Page A, Ataman-Önal Y, Choquet-Kastylevsky G, Fliniaux I, Le Bourhis X, Toillon RA, Bradshaw RA, Hondermarck H. Pro-nerve growth factor induces autocrine stimulation of breast cancer cell invasion through tropomyosin-related kinase A (TrkA) and sortilin protein. J Biol Chem. 2012;287:1923-31.

Vanhecke E, Adriaenssens E, Verbeke S, Meignan S, Germain E, Berteaux N, Nurcombe V, Le Bourhis X, Hondermarck H.Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival. Clin Cancer Res. 2011;17:1741-52.

Joubel A, Chalkley RJ, Medzihradszky KF, Hondermarck H, Burlingame AL. Identification of new p53 acetylation sites in COS-1 cells. Mol Cell Proteomics. 2009;8:1167-73.

Adriaenssens E, Vanhecke E, Saule P, Mougel A, Page A, Romon R, Nurcombe V, Le Bourhis X, Hondermarck H.Nerve growth factor is a potential therapeutic target in breast cancer. Cancer Res. 2008;68:346-51.

Hondermarck H, Tastet C, El Yazidi-Belkoura I, Toillon RA, Le Bourhis X. Proteomics of breast cancer: the quest for markers and therapeutic targets. J Proteome Res 2008;7:1403-11.

Collaboration

We have an Honours position for 2013 available in the group.

Project title: proNGF and its receptors in cancers.

Description: We have previously identified pro-nerve growth factor as an important player in breast cancer metastasis and the objective of the project will be to explore other types of cancer to determine if proNGF could also be involved and useful as a biomarker and/or therapeutic target.

If you are interested please contact hubert.hondermarck@newcastle.edu.au

Fields of Research

Centres and Groups

Centre

• Hunter Medical Research Institute
• PRC - Priority Research Centre for Cancer

Group

• Hunter Medical Research Institute - Cancer

Teaching

Teaching keywords

• Biochemistry
• Cancer Cell Biology

Teaching expertise

Head of discipline for Medical Biochemistry.